How a scientist accelerates target validation with Causaly
How a scientist accelerates target validation with Causaly
Challenges
In drug discovery, identifying and validating new targets is one of the most critical and high-risk stages of the pipeline. For a neuroscientist at a Top 50 global pharmaceutical company, this means rigorously assessing mechanistic relevance, safety signals, and the depth of supporting evidence before advancing a target.
She begins with a broad list of potential targets generated from published literature and internal research. The challenge is narrowing that list to those with strong biological rationale, manageable safety risk, and meaningful therapeutic potential.
Traditionally, this process required extensive manual review of publications, cross-referencing disparate data sources, and piecing together fragmented insights. Evaluating disease pathways, molecular mechanisms, side effect profiles, and competitive activity could take days per target, with no guarantee of completeness. The result was slow decision-making and limited confidence in prioritization.
How Causaly Helped
From a long list to the right list
Using Causaly Agentic Research, she was able to quickly surfaces the most relevant and up-to-date evidence related to each target. Instead of manually sifting through search results, she focused on high-value insights grounded in peer-reviewed literature and structured data.
This allows her to quickly assess:
- Target–disease associations
- Strength and consistency of mechanistic evidence
- Emerging findings that could shift prioritization
What once required hours of screening abstracts now takes minutes.
Diving into relationships with Bio Graph
For more depth, she uses Causaly's Bio Graph to visually explore how each target connects to disease biology, including pathways, molecular interactions, phenotypes, and known safety signals. Rather than stitching together insights from multiple tools, she was able to interrogate the biological network in one unified environment.
This helps her answer critical questions:
- Does the target play a credible, causal role in disease pathology?
- What downstream pathways are implicated?
- Are there known adverse events or mechanistic red flags?
The visual and evidence-linked exploration accelerates confident decision-making, helping her advance the right targets and deprioritize weaker candidates earlier.
Understanding the competitive landscape
She also needed to stay on top of the competitive landscape because validation does not stop at biology. Commercial viability and competitive saturation are equally important. With Causaly's pipeline graph, she benchmarks:
- How well-characterized a target already is
- Existing compounds in development
- Clinical trial activity
- Areas of therapeutic white space
By integrating literature, clinical trial data, and emerging research trends, she gains a clear view of where differentiation is possible and where duplication risk is high.
Deep analysis without the bottlenecks
The real power of Causaly, she says, lies in its ability to streamline the discovery and validation process. Causaly brings discovery, validation, and competitive assessment into a single interface.
Bio Graph reveals the underlying biological evidence supporting each target. Agentic research surfaces the most relevant publications instantly, with key supporting sentences that are extractable directly from source literature, providing transparency and auditability for internal discussions.
Instead of cross-checking multiple databases and manually compiling summaries, she can move seamlessly from mechanistic validation to market assessment, with higher confidence and dramatically less effort.
Impact
By using Causaly, she was able to significantly reduces the time required to validate neurological drug targets. Hours of manual literature review are replaced with rapid, evidence-backed exploration.
This shift enables:
- Faster target prioritization
- Earlier identification of risk
- More confident, data-driven internal recommendations
- Greater focus on high-value scientific thinking rather than manual data gathering
De-Risking Discovery
With Causaly, this team has transformed how they evaluate new neurological targets. High-risk candidates are filtered earlier. Resources are focused where biological plausibility and competitive opportunity align.
By unifying search, biological interrogation, and competitive intelligence, Causaly enables confident target prioritization, reduces discovery risk, and accelerates progress through the pipeline.
Causaly is a much better way of seeing the information as well as the bigger picture - instead of reviewing only a few papers and only seeing connections if you get lucky.
Get started with Causaly
Ready to transform the way your R&D teams discover and deliver? Take the first step - see Causaly for yourself.
Request a demo